美国子宫内膜异位症女性的短效与长效阿片类药物使用情况:一项基于人群的索赔研究
该回顾性队列研究基于Truven MarketScan商业数据库2011年1月1日至2016年12月31日数据,纳入58 472例子宫内膜异位症女性,发现61.7%在研究期间填写过阿片类药物处方,其中超过95%仅使用短效阿片类药物。填写阿片类药物处方的患者基线合并症更多,尤其是妇科和慢性疼痛合并症,且子宫内膜异位症相关药物使用更多。结论指出阿片类药物并非子宫内膜异位症的推荐治疗,但超过半数患者在首次诊断后1年内填写了阿片类药物处方。
要点
- 子宫内膜异位症女性中61.7%在研究期间填写过阿片类药物处方。
- 超过95%仅使用短效阿片类药物,4.1%同时使用短效和长效,0.6%仅使用长效。
- 同时使用长效和短效阿片类药物的患者阿片类药物总供应天数、覆盖比例和吗啡等效日剂量最高。
核心结论
- 尽管阿片类药物不是子宫内膜异位症的推荐治疗,但超过半数患者在首次记录诊断后1年内填写了阿片类药物处方。
- 填写阿片类药物处方的患者倾向于使用更多子宫内膜异位症相关药物,并具有更高的合并症负担。
- 需要进一步研究以更好地理解子宫内膜异位症中阿片类药物使用的相关原因和结局,并确定对使用阿片类药物的患者是否有更有效的疼痛管理治疗方案。
研究设计与样本
- 回顾性队列分析,数据来自Truven MarketScan商业数据库2011年1月1日至2016年12月31日。
- 子宫内膜异位症定义为具有1个住院或2个门诊子宫内膜异位症诊断代码的女性。
- 在诊断后12个月内填写阿片类药物处方的女性归入阿片类药物队列,未填写者归入非阿片类药物队列。
- 数据集包括58 472例子宫内膜异位症女性。
主要发现
- 61.7%的女性在研究期间填写了阿片类药物处方。
- 超过95%仅填写短效阿片类药物处方,4.1%同时填写短效和长效/缓释阿片类药物处方,0.6%仅填写长效/缓释阿片类药物处方。
- 填写阿片类药物处方的患者相比未填写者具有更高的基线合并症,尤其是妇科和慢性疼痛合并症,以及更多的子宫内膜异位症相关药物使用。
- 同时填写长效和短效阿片类药物处方的患者具有最高的阿片类药物总供应天数、处方覆盖天数比例和吗啡等效日剂量。
- 这些患者还具有最高比例的阿片类药物转换和剂量增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To determine the prevalence and pattern of opioid use in endometriosis and the characteristics of patients prescribed an opioid using medical insurance claims data. DESIGN: We performed a retrospective cohort analysis of data from the Truven MarketScan Commercial database for the period of January 1, 2011 to December 31, 2016. SETTING: The Truven database includes inpatient, outpatient, and prescription claims covering more than 115 million unique individuals and over 36 million inpatient hospital discharges across multiple payer types and all 50 states. PATIENTS: Women with endometriosis were defined as those with 1 inpatient or 2 outpatient codes for endometriosis. INTERVENTIONS: No interventions were assigned. Women who filled an opioid prescription within 12 months of diagnosis were placed in the opioid cohort and women who did not fill an opioid prescription were placed in the nonopioid cohort. MEASUREMENTS AND MAIN RESULTS: Baseline characteristics were evaluated 12 months preindex (date of the first diagnosis) and opioid use was assessed for 12 months after the index date. The dataset included 58 472 women with endometriosis. Of these, 61.7% filled an opioid prescription during the study period. More than 95% filled prescriptions for short-acting opioids (SAOs) only, 4.1% filled prescriptions for both SAOs and extended-release/long-acting opioids (LAOs), and 0.6% filled prescriptions for LAOs only. Patients who filled an opioid prescription had higher baseline comorbidities (especially gynecologic and chronic pain comorbidities) and endometriosis-related medication use compared with patients who did not fill an opioid prescription during the study period. Patients who filled both LAO and SAO prescriptions had the highest total days' supply of opioids, the proportion of days covered by prescriptions, and morphine equivalent daily dose. These patients also had the highest proportions of opioid switching and dose augmentation. Statistical trends in data were not substantially altered when analyses excluded patients with chronic pain comorbidities or surgical opioid prescriptions. CONCLUSION: Although opioids are not a recommended treatment for endometriosis, more than half of our cohort filled an opioid prescription within 1 year after a first recorded diagnosis of endometriosis. Patients who filled an opioid prescription tended to use more endometriosis-related medications and have a higher comorbidity burden. Additional research is necessary to better understand the reasons and outcomes associated with opioid utilization in endometriosis and to determine if there is a more effective pain management treatment plan for patients taking opioids.
引用
- As-Sanie S, Soliman AM, Evans K, et al. Short-acting and Long-acting Opioids Utilization among Women Diagnosed with Endometriosis in the United States: A Population-based Claims Study. J Minim Invasive Gynecol. 2020. PMID: 32531340. doi:10.1016/j.jmig.2020.05.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。